Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2009 2
2010 3
2011 1
2012 1
2013 1
2014 2
2015 2
2016 2
2017 2
2018 3
2019 3
2020 5
2021 7
2022 9
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.
Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O, Karanam AK, Wu M, Tankó LB, Schubert-Tennigkeit AA, Papanicolaou DA, Lloyd TE, Needham M, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Aoki M, Katsuno M, Morihata H, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Zhang Auberson L; RESILIENT Study Extension Group. Amato AA, et al. Neurology. 2021 Mar 23;96(12):e1595-e1607. doi: 10.1212/WNL.0000000000011626. Epub 2021 Feb 17. Neurology. 2021. PMID: 33597289 Free PMC article. Clinical Trial.
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY).
Chisari CG, Bianco A, Brescia Morra V, Calabrese M, Capone F, Cavalla P, Chiavazza C, Comi C, Danni M, Filippi M, Iaffaldano P, Lanzillo R, Lo Fermo S, Lucisano A, Lugaresi A, Lus G, Marfia GA, Marinelli F, Mirabella M, Moiola L, Perin C, Realmuto S, Toscano S, Trojano M, Vecchio D, Patti F; Italian MS Registry. Chisari CG, et al. Among authors: bianco a. Neurotherapeutics. 2023 Oct;20(6):1696-1706. doi: 10.1007/s13311-023-01415-y. Epub 2023 Aug 23. Neurotherapeutics. 2023. PMID: 37610702 Free PMC article.
Cyclophosphamide in highly aggressive Marburg-like multiple sclerosis.
Nicoletti T, Bianco A, Lucchini M, Gaudino S, Frisullo G, Mirabella M. Nicoletti T, et al. Among authors: bianco a. Ther Adv Neurol Disord. 2021 Oct 10;14:17562864211050028. doi: 10.1177/17562864211050028. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34659455 Free PMC article. No abstract available.
A true isolated cognitive relapse in multiple sclerosis.
Pozzilli V, Cruciani A, Capone F, Motolese F, Rossi M, Pilato F, Bianco A, Mirabella M, Giuffré GM, Calabria LF, Di Lazzaro V. Pozzilli V, et al. Among authors: bianco a. Neurol Sci. 2023 Jan;44(1):339-342. doi: 10.1007/s10072-022-06441-w. Epub 2022 Oct 8. Neurol Sci. 2023. PMID: 36207651
Defining the disease course of TNFα blockers-associated Multiple Sclerosis.
Lucchini M, Giuffrè GM, Nociti V, Bianco A, De Fino C, Losavio FA, Presicce G, Calabresi P, Mirabella M. Lucchini M, et al. Among authors: bianco a. J Neuroimmunol. 2021 Apr 15;353:577525. doi: 10.1016/j.jneuroim.2021.577525. Epub 2021 Feb 20. J Neuroimmunol. 2021. PMID: 33647875
Clinically relevant increases in serum neurofilament light chain and glial fibrillary acidic protein in patients with Susac syndrome.
Plantone D, Sabatelli E, Locci S, Marrodan M, Laakso SM, Mateen FJ, Feresiadou A, Buelens T, Bianco A, Fiol MP, Correale J, Tienari P, Calabresi P, De Stefano N, Iorio R. Plantone D, et al. Among authors: bianco a. Eur J Neurol. 2023 Oct;30(10):3256-3264. doi: 10.1111/ene.15939. Epub 2023 Jun 29. Eur J Neurol. 2023. PMID: 37335505
A case report of cladribine-induced IgG4-associated liver injury.
Biolato M, Bianco A, Giustiniani MC, Mirabella M, Pompili M. Biolato M, et al. Among authors: bianco a. Acta Neurol Belg. 2024 Apr 8. doi: 10.1007/s13760-024-02551-8. Online ahead of print. Acta Neurol Belg. 2024. PMID: 38587719 No abstract available.
Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients.
Bianco A, Lucchini M, Totaro R, Fantozzi R, De Luca G, Di Lemme S, Presicce G, Evangelista L, Di Tommaso V, Pastorino R, De Fino C, De Arcangelis V, Centonze D, Mirabella M. Bianco A, et al. Neurotherapeutics. 2021 Oct;18(4):2598-2607. doi: 10.1007/s13311-021-01106-6. Epub 2021 Sep 7. Neurotherapeutics. 2021. PMID: 34494237 Free PMC article.
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
Bisecco A, Matrone F, Capobianco M, De Luca G, Filippi M, Granella F, Lus G, Marfia GA, Mirabella M, Patti F, Trojano M, Mascolo A, Copetti M, Tedeschi G, Gallo A; OCREVID study group on behalf of the Italian MS Register. Bisecco A, et al. J Neurol. 2024 Feb;271(2):699-710. doi: 10.1007/s00415-023-12084-4. Epub 2023 Nov 20. J Neurol. 2024. PMID: 37982852 Free PMC article.
44 results